Results 131 to 140 of about 106,112 (301)
Dosing Biologic Drugs for Patients with Obesity: One Size Does NOT Fit All
Arthritis &Rheumatology, Accepted Article.
Stephen J. Balevic +2 more
wiley +1 more source
Abstract Objective This study aimed to identify risk factors and develop a predictive scoring system for autoimmune‐associated epilepsy in subjects with autoimmune encephalitis presenting with new onset refractory status epilepticus (NORSE). Methods This retrospective, multicenter, cohort study included subjects who presented with NORSE at the onset of
Simona Lattanzi +50 more
wiley +1 more source
IL‐6 from RTECs upregulates TGF‐β in macrophages, promoting fibroblast transdifferentiation. Isorhamnetin inhibits this effect. ABSTRACT Chronic kidney disease (CKD) is a major global health issue. Kidney fibrosis is a key mechanism leading to end‐stage renal disease.
Weifei Liang +8 more
wiley +1 more source
Abstract Objective To determine if multiplex autoantibody arrays can identify novel biomarker signatures in children with one or multiple autoimmune diseases (polyautoimmunity). Methods Plasma collected from children (18 years or younger) in the Boston Children's Hospital Precision Link Biobank for Health Discovery between January 2007 and June 2021 ...
Nan Du +7 more
wiley +1 more source
Tocilizumab combined with high‐dose methylprednisolone improved outcomes in children with acute necrotizing encephalopathy. A dose of 30 mg/(kg·day) may be more effective than 20 mg/(kg·day). ABSTRACT Importance Acute necrotizing encephalopathy (ANE) is a rare but life‐threatening pediatric neurological disorder characterized by rapid progression and ...
Fei Li +4 more
wiley +1 more source
Interleukin‐6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors [PDF]
Tetsuo Kobayashi +8 more
openalex +1 more source
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said +10 more
wiley +1 more source
A case of severe COVID-19 treated by tocilizumab and anticoagulation
Toshihiro Kubo +7 more
openalex +2 more sources
Should tocilizumab be the first line treatment for neuromyelitis optica together with rituximab?
Raja Sawaya, G. Saab, Hussein Moussa
openalex +1 more source

